Compare · MDLN vs SENS
MDLN vs SENS
Side-by-side comparison of Medline Inc. (MDLN) and Senseonics Holdings Inc. (SENS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDLN and SENS operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MDLN is the larger of the two at $48.08B, about 45.1x SENS ($1.07B).
- MDLN has been more active in the news (7 items in the past 4 weeks vs 5 for SENS).
- MDLN has more recent analyst coverage (25 ratings vs 8 for SENS).
- Company
- Medline Inc.
- Senseonics Holdings Inc.
- Price
- $35.95-1.74%
- $7.75-5.66%
- Market cap
- $48.08B
- $1.07B
- 1M return
- +11.97%
- -
- 1Y return
- -11.77%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- AMEX
- IPO
- 2025
- News (4w)
- 7
- 5
- Recent ratings
- 25
- 8
Senseonics Holdings Inc.
Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to 90 and 180 days. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.
Latest MDLN
- SEC Form 8-K filed by Medline Inc.
- Medline to build Midwestern network with new 800,000-square-foot facility in Van Buren Township, Mich.
- SEC Form 4 filed by Medline Inc.
- Medline launches enhanced TrackPoint™ to simplify inventory management for post-acute care
- SEC Form 4 filed by Medline Inc.
- MEDLINE INC. MDLN INVESTORS: Contact Kirby McInerney LLP About the Firm’s Securities Investigation Following 12.8% Share Drop
- Medline to report third quarter 2026 results on November 4, 2026
- INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Medline Inc. to Contact Law Firm
- Medline announces participation in the Morgan Stanley 24th Annual Global Healthcare Conference
- SEC Form 4 filed by Chief Executive Officer Boyle James M
Latest SENS
- Barclays initiated coverage on Senseonics with a new price target
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- SEC Form 4 filed by Senseonics Holdings Inc.
- Senseonics Announces Strategic Partnership with Beta Bionics to Integrate Eversense® 365 with the iLet® Bionic Pancreas
- Senseonics To Participate in Upcoming Institutional Investor Conferences
- Director Roeder Douglas A bought $125,300 worth of shares (13,953 units at $8.98), increasing direct ownership by 9% to 171,191 units (SEC Form 4)
- SEC Form 10-Q filed by Senseonics Holdings Inc.
- Senseonics Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits